Hussman Strategic Advisors, Inc. Sage Therapeutics, Inc. Transaction History

Hussman Strategic Advisors, Inc.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 03, 2023	SELL	$40.65 - $59.54 $552,840 - $809,744	-13,600 Reduced 52.31%	12,400 $583,000
Q4 2021 Jan 31, 2022	SELL	$37.06 - $47.11 $1.79 Million - $2.28 Million	-48,400 Reduced 65.05%	26,000 $1.11 Million
Q2 2021 Aug 03, 2021	BUY	$54.88 - $79.29 $4.08 Million - $5.9 Million	74,400 New	74,400 $4.23 Million

222

52.7M

207K

191K

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $641M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

Get notified when there are updates to the investment portfolio of Hussman Strategic Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on Hussman Strategic Advisors, Inc. with notifications on news.